Silence Therapeutics plc (ADR)

General ticker "SLN" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $222.6M (TTM average)

Silence Therapeutics plc (ADR) follows the US Stock Market performance with the rate: 43.5%.

Estimated limits based on current volatility of 4.9%: low 10.71$, high 11.81$

Factors to consider:

  • Earnings expected soon, date: 2026-08-06 bmo
  • Total employees count: 116 as of 2024
  • Top business risk factors: Need for additional capital, No approved products, Sirna development failure, Third-party risks, Regulatory and compliance
  • Earnings for 3 months up through Q1 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2025-12-31 to 2027-12-31

  • 2025-12-31 to 2026-12-31 estimated range: [4.35$, 9.95$]
  • 2026-12-31 to 2027-12-31 estimated range: [3.68$, 8.64$]

Similar symbols

Short-term SLN quotes

Long-term SLN plot with estimates

Financial data

YTD 2023-12-31 2024-12-31 2025-12-31
Operating Revenue £25.38MM £43.26MM £0.56MM
Operating Expenses £74.98MM £106.58MM £91.64MM
Operating Income £-49.60MM £-63.32MM £-91.08MM
Non-Operating Income £-0.71MM £18.86MM £2.48MM
Interest Expense £0.03MM £0.00MM £0.00MM
R&D Expense £44.02MM £67.88MM £67.75MM
Income(Loss) £-50.31MM £-44.46MM £-88.60MM
Taxes £-7.04MM £0.84MM £0.01MM
Net Income(Loss)* £-43.27MM £-45.31MM £-88.61MM
Stockholders Equity £21.99MM £134.02MM £62.30MM
Assets £119.45MM £202.63MM £131.44MM
Operating Cash Flow £-39.35MM £-54.05MM £-62.27MM
Capital expenditure £0.04MM £0.17MM £0.06MM
Investing Cash Flow £16.43MM £-17.55MM £-47.99MM
Financing Cash Flow £25.16MM £113.54MM £0.01MM
Earnings Per Share** £-3.50 £-2.94 £-1.88
Ordinary share to ADR 1.00x 1.00x 1.00x

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.